Blog

In the development of innovative drugs, the progress of the process development of the IND phase of the API often directly affects the subsequent formulation development, preclinical and clinical research, and final commercialization. How to plan and manage the API process development in the IND phase, and how to do the quality control of theRead more

On December 9-10, 2019, the “Fifth Pharmaceutical Frontier Summit Forum” was held concurrently during the “Nanjing International Life and Health Technology Expo”, with the theme of “Leading Life Science and Technology, Empowering the Health Industry”, through academician reports and round tables Dialogues, special exchanges, exhibitions and other ways to gather innovative resources, focus on theRead more

Medicilon CEO Chun-Lin Chen gave a speech during the seminar where he shared his experience on IND filling for both US and China. Professor Shuangqing Peng had a topic on New Drug Safety Evaluation Approach. Dr. Baomin Xin, Medicilon VP of DMPK and BA, shared his experience on big molecule analytical approach and future trend,Read more

Medicilon’s IND application service platform has an in-depth understanding of the regulatory and policy environment of China and the United States and its technical requirements for chemical drugs. It can provide domestic customers with CFDA IND declaration and USFDA IND/ANDA declaration services; it can provide foreign customers with CFDA IND /ANDA declaration service. The serviceRead more

Medicilon provide the IND filing for the preclinical services. Medicilon could submit the application for both US FDA and CFDA for your new drug. Medicilon is the first CRO to offer preclinical animal testing service for the global pharmaceutical companies in China. Medicilon is the CRO that fulfill both the Chinese and US GLP standards.Read more